Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Summary

The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance a T - or NK cell mediated graft versus leukemia (GVL) effects. Nevertheless, one has to keep in mind a possible, yet unknown influence on modulation of clinical GVHD.

Timeline

Start

2008-04

Primary completion

2011-01

Completion

2011-01

Outcome

Outcome not reported

Stopped (Enrollment): “Low recruitment, scientific rationale not applicable anymore to all patients and possible induction of GvHD by the study drug”

Drugs

Indications